Resources in German

As a biopharmaceutical company headquartered in Allschwil/Basel, Switzerland, we have many people interested in reading more about the company in German.

Als schweizerisches Unternehmen stellen wir interessierten Personen auf dieser Seite wesentliche Informationen über unser Unternehmen in deutscher Sprache zur Verfügung.

Medieninformationen

Idorsia bietet ausgewählte Medienmitteilungen und Informationsmaterial auch in deutscher Sprache an.

Latest news

17 Mar 2023

On World Sleep Day Idorsia highlights the publication of a global study on the economic and societal impact of chronic insomnia disorder

31 Jan 2023

Idorsia submits European marketing authorisation application for aprocitentan for the treatment of patients with resistant hypertension

20 Dec 2022

Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension

15 Dec 2022

Idorsia initiates OPUS a Phase 3 program to investigate cenerimod for the treatment of patients with systemic lupus erythematosus

12 Dec 2022

Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS Drugs

05 Dec 2022

Swissmedic erteilt Zulassung für QUVIVIQ (Daridorexant) – Erstes Medikament seiner Klasse für Behandlungen chronischer Schlaflosigkeit, das sowohl die nächtlichen Symptome als auch die Leistungsfähigkeit am Tag (Tagesaktivität) verbessert

15 Nov 2022

QUVIVIQ (daridorexant) – Europe’s first dual orexin receptor antagonist – is now available for patients with chronic insomnia disorder in Italy and Germany

13 Nov 2022

Idorsia gratuliert seiner Chief Scientific Officer Martine Clozel, die von der Initiative Schweiz mit dem jährlichen Prix Suisse Award ausgezeichnet wurde

07 Nov 2022

The Lancet and AHA late-breaking science session reports significant and sustained effect of aprocitentan on lowering blood pressure for patients with resistant hypertension

10 May 2022

Phase 2a study results in binge eating disorder

03 May 2022

Europe’s first dual orexin receptor antagonist – QUVIVIQ (daridorexant) – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder

02 May 2022

Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia

20 Apr 2022

PIVLAZ (clazosentan) – Idorsia’s first commercial product – now available for patients in Japan

04 Apr 2022

The Journal of Neurosurgery reports impact of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage

10 Mar 2022

New data for daridorexant in patients with insomnia disorder – including long-term safety and efficacy – to be presented at World Sleep 2022

26 Jan 2022

Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada

20 Jan 2022

The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia

12 Jan 2022

Jennifer Aniston partners with Idorsia U.S. to launch ‘Seize the Night & Day’ campaign inspiring Americans to understand their relationship with sleep

10 Jan 2022

Idorsia presents at the 40th J.P. Morgan Healthcare Conference – Ready for first product launches – QUVIVIQ (daridorexant) approved by the US FDA

28 Jul 2021

Idorsia announces the reference share price and the initial conversion price of convertible bonds successfully placed today

Ad hoc announcements pursuant to Art. 53 LR

Ad hoc announcements pursuant to Art. 53 LR have been classified from 2021 onwards. A full archive of press releases can be found under the "All" tab.